EP 1482922 A4 20050608 - AGENTS FOR CORNEAL OR INTRASTROMAL ADMINISTRATION TO TREAT OR PREVENT DISORDERS OF THE EYE
Title (en)
AGENTS FOR CORNEAL OR INTRASTROMAL ADMINISTRATION TO TREAT OR PREVENT DISORDERS OF THE EYE
Title (de)
MITTEL FÜR DIE CORNEALE ODER INTRASTROMALE VERABREICHUNG ZUR BEHANDLUNG ODER PRÄVENTION VON ERKRANKUNGEN DES AUGES
Title (fr)
AGENTS POUR UNE ADMINISTRATION CORNEENNE OU INTRASTROMALE POUR TRAITER OU EMPECHER LES TROUBLES OCULAIRES
Publication
Application
Priority
- US 0307700 W 20030314
- US 36397902 P 20020314
Abstract (en)
[origin: WO03077898A1] Methods and preparations for treating disorders of the eye and/or causing dissolution of corneal proteoglycans and organized healing of corneal stroma, softening of the cornea for non-surgical refractive correction of eyesight, removing corneal haze and opacification, inhibiting fibroblasts and preventing corneal fibrosis and scar formation, treating pterigiums and treating corneal neovascularization as well as iris neovascularization. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) antimetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytadine, guanine, guanitadine, guanidinium, guanidinium chloride, guanidinium salts, thymidine, thymitadine, uradine, uracil, cysteine), reduced thioctic acid, uric acid, calcium acetyl salicylate, ammonium sulfate, isopropyl alcohol, ethanol, polyethylene glycol, polypropylene glycol or other compounds capable of causing nonenzymatic dissoultion of the corneal protoeglycans or f) any of the possible combinations thereof, are administered to the eye in therapeutically effective amounts.
IPC 1-7
IPC 8 full level
A61K 31/17 (2006.01); A61K 31/40 (2006.01); A61K 31/407 (2006.01); A61K 31/77 (2006.01); A61K 45/00 (2006.01); A61P 9/00 (2006.01); A61P 27/00 (2006.01); A61P 27/06 (2006.01); A61P 27/10 (2006.01)
CPC (source: EP KR)
A61K 31/17 (2013.01 - EP KR); A61K 31/40 (2013.01 - EP); A61K 31/513 (2013.01 - KR); A61K 31/52 (2013.01 - KR); A61K 31/7076 (2013.01 - KR); A61P 9/00 (2017.12 - EP); A61P 27/00 (2017.12 - EP); A61P 27/02 (2017.12 - EP); A61P 27/06 (2017.12 - EP); A61P 27/10 (2017.12 - EP)
Citation (search report)
- [X] WO 0051620 A1 20000908 - VITREO RETINAL TECHNOLOGIES IN [US]
- [E] WO 03068166 A2 20030821 - VITREO RETINAL TECHNOLOGIES IN [US]
- See references of WO 03077898A1
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
DOCDB simple family (publication)
WO 03077898 A1 20030925; AU 2003213858 A1 20030929; AU 2009201897 A1 20090604; AU 2009201897 B2 20110915; BR 0308403 A 20050118; CA 2478965 A1 20030925; CN 1642536 A 20050720; EP 1482922 A1 20041208; EP 1482922 A4 20050608; JP 2005522464 A 20050728; KR 20040094793 A 20041110; MX PA04008776 A 20050419; RU 2004129761 A 20050610; RU 2363459 C2 20090810
DOCDB simple family (application)
US 0307700 W 20030314; AU 2003213858 A 20030314; AU 2009201897 A 20090513; BR 0308403 A 20030314; CA 2478965 A 20030314; CN 03805968 A 20030314; EP 03711552 A 20030314; JP 2003575951 A 20030314; KR 20047014329 A 20030314; MX PA04008776 A 20030314; RU 2004129761 A 20030314